REG - Novacyt S.A. - Notice of Results

Novacyt SAAnnouncement

17/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230417:nRSQ3393Wa&default-theme=true

RNS Number : 3393W  Novacyt S.A.  17 April 2023

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Notice of Full Year 2022 Results and Investor Presentation

 

Paris, France and Eastleigh, UK - 17 April 2023 - Novacyt S.A. (EURONEXT
GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical
diagnostics, announces that it will report its audited financial results for
the year ended 31 December 2022 on Thursday, 27 April 2023.

Investor webinar

An investor webinar presentation by James McCarthy, Acting Chief Executive
Officer, and Steve Gibson, Group Finance Director, will take place at 12.00pm
BST on Thursday, 27 April 2023.

The webinar is open to all existing and potential investors and will consist
of a presentation followed by a Q&A session, held on the Investor Meet
Company platform. Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 9.00am the day before the meeting or at any time
during the live presentation. Automated French subtitling will be available
throughout the presentation.

Investors can sign up to Investor Meet Company for free and add to meet
NOVACYT S.A. via:

https://www.investormeetcompany.com/novacyt-sa/register-investor
(https://www.investormeetcompany.com/novacyt-sa/register-investor)

Investors who already follow NOVACYT S.A. on the Investor Meet Company
platform will automatically be invited.

 

- End -

Contacts

Novacyt SA

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Numis (Joint Broker)

James Black / Freddie Barnfield / Duncan Monteith

+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10 (mailto:r.durgetto@allegrafinance.com)

r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) ;
y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

Walbrook PR

Paul McManus/ Stephanie Cuthbert/ Anna Dunphy

+44 (0)20 7933 8780 (mailto:novacyt@walbrookpr.com)

novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio
of in vitro and molecular diagnostic tests for a wide range of infectious
diseases, enabling faster, more accurate, accessible testing to improve
healthcare outcomes. The Company provides customers with a seamless
sample-to-result workflow using its integrated and scalable
instrumentation/solutions. The Company specialises in the design, manufacture,
and supply of real-time PCR kits, reagents and a full range of laboratory and
qPCR instrumentation for molecular biology research and clinical use. Novacyt
offers one of the world's most varied and comprehensive range of qPCR assays,
covering human, veterinary, biodefence, environmental, agriculture and food
testing.

Novacyt is headquartered in Vélizy in France with offices in Stokesley and
Eastleigh, UK, and is listed on the London Stock Exchange's AIM market
("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREAELSFDXDEFA